 PALO ALTO, Calif., June 14, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO, a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that on June 1, 2021, the compensation committee of BridgeBios board of directors granted 21 new employees restricted stock units for an aggregate of 47,963 shares of the Companys common stock. All of the above-described awards were made under BridgeBios 2019 Inducement Equity Plan the Plan. 